Moleculin Reports Higher AML Complete Remission Rates And Durability With Additional Interim Subject Data
Portfolio Pulse from Benzinga Newsdesk
Moleculin Biotech, Inc. (MBRX) announced positive interim data for Annamycin in its AML clinical development program, showing increased complete remission rates. The data supports advancing to a Phase 2 trial aimed at New Drug Approval. A virtual AML Clinical Day is scheduled to discuss these results.
May 07, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moleculin announced positive interim data for Annamycin in AML trials, showing increased remission rates and supporting the advancement to a Phase 2 trial.
The positive interim data for Annamycin in AML trials indicates a successful development path towards a Phase 2 trial and potential New Drug Approval. This progress is likely to be viewed positively by investors, potentially leading to an increase in MBRX's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100